Phase 2
Completed N=6
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
Source: ClinicalTrials.gov NCT01372384 ↗Enrolled (actual)
6
Serious AEs
16.7%
Results posted
Nov 2015
Primary outcomePrimary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days
Summary
This open-label study will assess the efficacy and safety of Tarceva (Erlotinib) in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who have not received previous chemotherapy for their disease and who present epidermal growth factor receptor mutations. Patients will receive Tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (Tumour Assessments According to RECIST Criteria) |
223 | — |
| SECONDARY Objective Response Rate (Investigator Assessed) |
83.3; 16.7; 33.3; 33.3; 33.3; 33.3 | 0.045 sig |
| SECONDARY Safety: Incidence of Adverse Events |
6; 1 | — |
| SECONDARY Overall Survival |
401 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Locally advanced (Stage IIIB), metastatic (Stage IV) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR)
- At least one measurable lesion according to RECIST criteria
- European Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate hematological, liver and renal function
- Patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible
Exclusion Criteria
- Previous chemotherapy or therapy against EGFR for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized >/= 6 months before entering the study)
- History of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (Gleason </= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years
- Symptomatic cerebral metastases
- Any significant ophthalmologic abnormality
- Use of coumarins
- Pregnant or breast-feeding women
- Pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)
Data sourced from ClinicalTrials.gov (NCT01372384). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.